Answers are grounded in this paper and cite their sources.
Demonstrates the enhanced antitumor efficacy of a microbial system in cancer, suggesting a novel immunotherapeutic approach.
The response rate of oncolytic microbe-triggered cancer immunotherapies are commonly restricted by in vivo dose-dependent toxicity. To address the limitation, we exploited the selective growth advantage conferred by tetrathionate respiration in inflamed tissue to engineer Salmonella Typhimurium (S. Typhimurium) VNP20009 into a self-amplifying oncolytic system with enhanced antitumor efficacy. The hydrogen sulfide (H2S) donor-anchored, biocompatible lipids-encapsulated VNP20009 exhibits good intratumoral enrichment after intravenous administration in tumor-bearing mice. In the inflammatory tumor microenvironment, H2S released from the donor can be oxidized to tetrathionate, which promotes the proliferation of VNP20009, leading to a marked increase compared to the bare VNP20009. This self-reinforced reproduction augments the activation of microbe-mediated immunogenic pyroptosis in the tumor, thereby triggering a significant immunotherapeutic effect in orthotopic breast tumor-bearing and melanoma-bearing mouse models. This study offers a potential strategy for developing high-effectiveness and low-side effect oncolytic microbe biotherapeutics in cancer treatment.
No takes yet. Share an insight, caveat, or question.
Yu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: